title: [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
abstract: OBJECTIVE
  To explore the therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation (HSCY) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
  
  
  METHODS
  Retrospective reviews were conducted for 46 patients with MDS (n = 14) and AML (n = 32) on a therapy of decitabine prior to allo-HSCT between September 2009 and February 2013.
  
  
  RESULTS
  In MDS patients, complete remission (CR, n = 10), partial remission (PR, n = 2) and stable disease (SD, n = 1) were achieved prior to HSCT. And the remission rate of one course was 10/14. After decitabine dosing, 17/32 patients achieved CR in 32 with AML and the remission rate of one course was 53.1％ (17/32) and effective rate of one course (CR+PR) achieves 78.1％ (25/32). Successful engraftment was attained in all MDS patients and 12/14 patients survived disease-free and one died of pneumonia after relapse. And 28 patients with AML attained successful engraftment after using decitabine prior to allo-HSCT and there were 20 disease-free survivors. Ten patients died and another lived with tumor. The incidences of acute and chronic graft-versus-host disease (GVHD) among evaluable patients were 4.3% (2/26) and 23.9% (11/46) respectively. After a median follow-up of 8 months for survivors, the treatment-related mortality was 23.9% (11/46). The 30-month disease-free survival (DFS) rate was 53.1% and 30-month overall survival rate after decitabine dosing 61.9%.
  
  
  CONCLUSIONS
  Thus decitabine is an effective therapy during bridge time to HSCT in patients with MDS and AML.
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Huifei
authors.initials: H
authors.lastname: Zheng
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Ma
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Panfeng
authors.initials: P
authors.lastname: Wang
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Yan
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Depei
authors.initials: D
authors.lastname: Wu
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China; Email: fuzhengzheng@suda.edu.cn.
authors.forename: Chengcheng
authors.initials: C
authors.lastname: Fu
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Huiying
authors.initials: H
authors.lastname: Qiu
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Tang
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Zhengming
authors.initials: Z
authors.lastname: Jin
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Han
authors.affiliation: Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, First Affiliated Hospital, Soochow University, Suzhou 215006, China.
authors.forename: Miao
authors.initials: M
authors.lastname: Miao
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives; D000077209:Decitabine; D018572:Disease-Free Survival; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D009190:Myelodysplastic Syndromes; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D000077209:Decitabine; D001374:Azacitidine